Compound having the general formula I: ** Formula ** or a pharmaceutically acceptable salt thereof, wherein: R1 is H or (1-6C alkyl)； R2 is NRbRc, (1-4C) alkyl, fluoroalkyl (1-4C), CF3, hydroxyalkyl (1-4C), - (1-4C alkyl) hetAr1, - (1-4C alkyl) NH (1-4C alkyl) , hetAr2, hetCic1, hetCic2, phenyl that is optionally substituted with NHSO2 (1-4C alkyl), or cycloalkyl (3-6C) that is optionally substituted with (1-4C alkyl), CN, OH, CF3, CO2 (alkyl 1 -4C) or CO2H； Rb is H or (1-6C alkyl)； Rc is H, alkyl (1-4C), hydroxyalkyl (1-4C), hetAr3, or phenyl, wherein said phenyl is optionally substituted with one or more substituents independently selected from halogen, CN, CF3 and -O (alkyl 1-4C), or NRbRc forms a 4-link heterocyclic ring having a nitrogen atom in the ring, wherein said heterocyclic ring is optionally substituted with one or more substituents independently selected from halogen, OH, (alkyl 1- 4C), alkoxy (1-4C), -OC (>； = O) (1-4C alkyl), NH2, - NHC (>； = O) O (1-4C alkyl) and hydroxyalkyl (1-4C), or NRbRc it forms a 5 to 6 link heterocyclic ring having a ring heteroatom that is nitrogen and optionally having a second ring heteroatom or a group selected from N, O and SO2, in which the heterocyclic ring is optionally substituted with one or more substituents independently selected from OH, halogen, CF3, (1-4C) alkyl, C O2 (alkyl 1-4C), CO2H, NH2, NHC (>； = O) O (alkyl 1-4C) and oxo.Compuesto que presenta la fórmula general I:**Fórmula** o una sal farmacéuticamente aceptable del mismo, en el que: R1 es H o (alquilo 1-6C)； R2 es NRbRc, alquilo(1-4C), fluoroalquilo(1-4C), CF3, hidroxialquilo(1-4C), -(alquilo 1-4C)hetAr1, -(alquilo 1- 4C)NH(alquilo 1-4C), hetAr2, hetCic1, hetCic2, fenilo que está opcionalmente sustituido con NHSO2(alquilo 1-4C), o cicloalquilo(3-6C) que está opcionalmente sustituido con (alquilo 1-4C), CN, OH, CF3, CO2(alquilo 1-4C) o CO2H； Rb es H o (alquilo 1-6C)； Rc es H, alquilo(1-4C), hidroxialquilo(1-4C), hetAr3, o fenilo, en el que dicho
